Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Periconceptional or first-trimester exposure to GLP-1 RAs are not significantly associated with HDP risk.
Atropine sulphate ophthalmic solution (0.01%) exhibited negligible rebound in myopia progression after treatment cessation following 3 years of.
Three external reference anchors were used to assess known-groups validity, based on clinician and study partner ratings of disease severity over time.
This comprehensive analysis is the first report characterizing the immunogenicity profile of ligelizumab.
Baseline 18F-FDG PET-derived metabolic and radiomic parameters do not provide meaningful incremental prognostic value beyond tumour burden and clinical factors.
In this post hoc analysis of SURMOUNT-5, a greater proportion of tirzepatide-treated participants in both responder groups achieved all body weight reduction thresholds versus semaglutide.
Body weight, disease status, and kidney function were shown to influence exposure, with dose adaptation only required in patients with kidney function impairment, as body weight and disease status had limited impact.
FREESIA-3, an open-label, multicenter, randomized, phase 3 study, will evaluate the real-world benefits and safety of nipocalimab in both standard- and high-risk pregnancies for FNAIT.
An initial belantamab mafodotin dose of 2.5 mg/kg for BVd yields deeper responses with minimal change in safety outcomes versus 1.9 mg/kg for patients with RRMM.
Axillary surgery remains the main predictor of long-term arm lymphoedema following locoregional radiotherapy for node-positive breast cancer, supporting de-escalation of.
In patients undergoing CRS for PMP, these results provide supportive evidence for the hemostatic efficacy of FC, consistent with the overall trial and prior studies, with a favorable safety profile.
No covariates were associated with ORR.
This ML-NMR provides an indirect comparison of injectable tirzepatide with oral semaglutide for weight management.
Our findings support the use of dihydropyridine calcium channel blockers as a preferred alternative to β-blockers for the management of high blood pressure in HFpEF.
Berotralstat significantly improved HRQoL versus placebo through 24 weeks and showed long-term beneficial effects through 96 weeks.
Luspatercept offers rapid and durable benefits by improving anemia-related symptoms and quality of life in patients with NTDT.
Picankibart provided effective skin clearance in Chinese participants by week 16.
Similar effects of belimumab on biomarker outcomes were observed within the induction groups.
Our results show the estimated MID for short-term NT-proBNP improvement in PAH and PH-ILD is remarkably similar at 48%.
Tirzepatide 15 mg and CagriSema achieve the greatest weight reduction, including ≥ 20% body weight loss.
The use of GLP-1 RAs is significantly associated with an increased risk of hair loss.
Selective omission of dexamethasone after the second weekly paclitaxel infusion was safe and well tolerated in this randomized trial.
In NPC patients achieving CR/PR after induction chemotherapy, IC + RT demonstrated a favorable safety profile compared with IC+CCRT.
This is first application of an integrated item-level IRT-BI-FREM approach in CD, enabling robust characterization of placebo response and identification of clinically relevant covariates.
Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation.
Mediation analysis supports a bile-acid-mediated suppression of inflammatory pathways linking microbial changes to antidepressant effects.
Obicetrapib lowered LDL-C, apoB and Lp(a).
Pelacarsen is a highly effective and well-tolerated Lp(a)-targeted therapy that substantially reduces the need for LA in patients with elevated Lp(a) and established CVD.
The preHD-ET for 36 weeks improves systemic aerobic capacity in ESRD patients.
Individualized NIs significantly improve QoL and nutritional status in patients with NPC undergoing radiation therapy, underscoring the importance of ongoing assessment-guided individualized nutritional support.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
